Get the Stockscreener App
11.07
4.47%
-0.555
Kalvista Pharmaceuticals Inc stock is traded at $11.07, with a volume of 358.84K.
It is down -4.47% in the last 24 hours and down -2.20% over the past month.
See More
Previous Close:
$11.63
Open:
$11.45
24h Volume:
358.84K
Relative Volume:
1.06
Market Cap:
$453.33M
Revenue:
-
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.5047
EPS:
-3.16
Net Cash Flow:
$-97.15M
1W Performance:
-5.77%
1M Performance:
-2.20%
6M Performance:
-8.41%
1Y Performance:
+28.14%
1-Day Range:
$10.78
$11.68
1-Week Range:
$10.01
$12.85
52-Week Range:
$7.21
$16.88
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
KalVista Secures $184M Financing for Sebetralstat Launch - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition in KalVista Pharmaceu - GuruFocus.com
KalVista sets pricing for $60 million stock offering By Investing.com - Investing.com Canada
KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering - Marketscreener.com
U.S. Dollar/Moldova Lei (USDMDL) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap UpWhat's Next? - MarketBeat
KalVista sets pricing for $60 million stock offering - Investing.com
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals - Barchart
Canadian Dollar/Australian Dollar (CADAUD) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - StockTitan
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - StockTitan
KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc. - Marketscreener.com
Emerald Advisers LLC Purchases 192,091 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
(KALV) Long Term Investment Analysis - Stock Traders Daily
Hereditary Angioedema Market Forecasted to Surge in Coming - openPR
sebetralstat shows promise in phase 3 HAE trial By Investing.com - Investing.com South Africa
sebetralstat shows promise in phase 3 HAE trial - Investing.com India
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology - The Bakersfield Californian
Hereditary Angioedema Market Size is Set for Rapid Growth as - openPR
(KALV) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Buys 3,314 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - Milton Daily Standard
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - MarketBeat
Plasma Protease C1 Inhibitor Market Size, Development Growth, - openPR
(KALV) Technical Data - Stock Traders Daily
Marshall Wace LLP Has $576,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
Sweden Hereditary Angioedema Therapeutics Market Size & Outlook, 2030 - Grand View Research
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stake Decreased by Dimensional Fund Advisors LP - MarketBeat
Kalvista shares hold Buy rating, price target on HAE study By Investing.com - Investing.com South Africa
Kalvista shares hold Buy rating, price target on HAE study - Investing.com
KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from HC Wainwright - MarketBeat
Kalvista asks 4 countries to OK sebetralstat as treatment for HAE - Angioedema News Today
KalVista Pharmaceuticals announces board election results - Investing.com India
KalVista Pharmaceuticals announces board election results By Investing.com - Investing.com Australia
Sebetralstat shows promise for anxiety in HAE attacks By Investing.com - Investing.com South Africa
Sebetralstat shows promise for anxiety in HAE attacks - Investing.com
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum - BioSpace
KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
KalVista Pharmaceuticals Inc [KALV] Shares Rise 3.95 % on Wednesday - Knox Daily
Susquehanna Fundamental Investments LLC Boosts Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
Analytical Lens: Exploring KalVista Pharmaceuticals Inc (KALV)’s Financial Story Through Ratios - The Dwinnex
It makes sense and dollars to buy KalVista Pharmaceuticals Inc (KALV) stock - SETE News
It would be worthwhile to take a closer look at KalVista Pharmaceuticals Inc (KALV) - US Post News
When the Price of (KALV) Talks, People Listen - Stock Traders Daily
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):